Earnings Mastery
  • Politics
  • Business
  • Investing
  • World
No Result
View All Result
  • Politics
  • Business
  • Investing
  • World
No Result
View All Result
Earnings Mastery
No Result
View All Result
Home Investing

Oracle stock sinks on revenue miss amid broader earnings slide

December 11, 2025
in Investing
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Oracle Corporation’s shares tumbled more than 6% in after-hours trading on Wednesday after fiscal second quarter revenue came in at $16.1 billion.

The figure marked a 14% rise from the prior year but fell short of Wall Street’s consensus of $16.2 billion.

The miss underscores investor scrutiny on the database giant’s aggressive expansion into AI-driven cloud infrastructure amid broader market jitters over earnings.​

Capex balloons on data centre buildout

Capital expenditures soared to $12 billion, well above the $8.4 billion anticipated by analysts.

This spike reflects Oracle’s massive investments in data centres to support surging demand for AI computing power.

CEO Larry Ellison’s firm highlighted commitments from major clients like OpenAI, fueling the infrastructure spend but raising debt concerns.

Shares, which had rallied post-September earnings on a $300 billion OpenAI deal, have since erased those gains.​

RPO climbs, but AI worries persist

Remaining performance obligations, a key backlog metric, grew 15% to $523 billion in the three months ended November.

This signals robust future revenue potential from AI contracts with partners, including Meta and Nvidia.

However, mounting borrowing needs and OpenAI’s long-term payment capacity have spooked investors, with credit default swaps at 2009 highs.​

The post Oracle stock sinks on revenue miss amid broader earnings slide appeared first on Invezz

Previous Post

Nvidia supplier SK Hynix confirms it is weighing US listing

Next Post

Novo Nordisk brings Ozempic to India as weight-loss demand accelerates

Next Post
Novo Nordisk brings Ozempic to India as weight-loss demand accelerates

Novo Nordisk brings Ozempic to India as weight-loss demand accelerates

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    Morning brief: Asian stocks rise as tech jitters persist; Trump moves to curb state-level AI rules

    December 12, 2025
    Australian government unveils $670M rescue plan for  Tomago aluminium smelter

    Australian government unveils $670M rescue plan for Tomago aluminium smelter

    December 12, 2025
    Lululemon shares jump after earnings beat and CEO exit announcement

    Lululemon shares jump after earnings beat and CEO exit announcement

    December 12, 2025
    Why Taiwan’s tech rally is brushing off global AI bubble fears

    Why Taiwan’s tech rally is brushing off global AI bubble fears

    December 12, 2025
    Novo Nordisk brings Ozempic to India as weight-loss demand accelerates

    Novo Nordisk brings Ozempic to India as weight-loss demand accelerates

    December 12, 2025

    Oracle stock sinks on revenue miss amid broader earnings slide

    December 11, 2025

    Disclaimer: EarningsMastery.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Popular

    Trump signs off on nationwide vaccine schedule review as CDC withdraws infant hep B guidance: ‘Fast track’

    Trump signs off on nationwide vaccine schedule review as CDC withdraws infant hep B guidance: ‘Fast track’

    December 7, 2025

    Latest

    Morning brief: Asian stocks rise as tech jitters persist; Trump moves to curb state-level AI rules

    December 12, 2025
    Australian government unveils $670M rescue plan for  Tomago aluminium smelter

    Australian government unveils $670M rescue plan for Tomago aluminium smelter

    December 12, 2025
    Lululemon shares jump after earnings beat and CEO exit announcement

    Lululemon shares jump after earnings beat and CEO exit announcement

    December 12, 2025
    • About us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 earningsmastery.com | All Rights Reserved

    No Result
    View All Result
    • Politics
    • Business
    • Investing
    • World

    Copyright © 2025 earningsmastery.com | All Rights Reserved